ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO666

Improving PPSV23 Vaccination Rates in Children with Nephrotic Syndrome

Session Information

  • Pediatric Nephrology - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Frierson, Emily, Baylor College of Medicine, Houston, Texas, United States
  • Vuong, Kimmy Thien, Baylor College of Medicine, Houston, Texas, United States
  • Fairless, Brandon M., Baylor College of Medicine, Houston, Texas, United States
  • Shah, Shweta S., Baylor College of Medicine, Houston, Texas, United States
  • Tal, Leyat, Baylor College of Medicine, Houston, Texas, United States

Children with nephrotic syndrome (NS) are at high risk for pneumococcal infections and the PPSV23 vaccine is recommended as part of the pneumococcal vaccine series. Barriers such as lack of availability in pediatrician clinics, inability to verify primary series status, and not addressing vaccinations has led to an inadequate rate of PPSV23 vaccination.


This is a quality improvement (QI) study that aims to increase PPSV23 vaccination rate among eligible NS patients admitted to the renal service to 75% by September 2023. An H&P template was created that includes a smart phrase prompting residents to review eligibility criteria for PPSV23 vaccination and vaccinate if appropriate. Patients older than 2 years of age that have completed primary pneumococcal vaccine series, and had not received Rituximab in the last 6 months were included. Pediatric residents were educated on QI study at the beginning of their renal rotation by fellows and sign placed in workroom to serve as a reminder. Process metrics included resident use of H&P and percent of eligible patients that refused vaccinations.


In 2-month period, 12 patients with NS were admitted to the renal service. 8 patients were up-to-date and 4 were eligible for PPSV23. Of eligible patients, 3 were identified, 2 received PPSV23 prior to discharge and 1 family declined. The H&P template was used for 7/12 (58%) of admissions and at hospital discharge 2/4 (50%) of eligible patients were up-to-date.


Increasing PPSV23 vaccination is important in decreasing serious pneumococcal infections. Our project showed improvement in identifying eligible NS patients with the implementation of the new H&P template. The participation from pediatric residents underscores value of simple interventions woven into work flow and work space.